US Patent

US8357690 — Methods of treatment using combination therapy

Method of Use · Assigned to Ambit Bioscience Corp · Expires 2031-02-26 · 5y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating a proliferative disease in a subject by administering a combination of AC220 and a nucleoside analog, a topoisomerase inhibitor, or an anthracycline.

USPTO Abstract

Provided herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of AC220 and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof.

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3661`	—	quizartinib-dihydrochloride
`U-3661`	—	quizartinib-dihydrochloride

Patent Metadata

Patent number: US8357690
Jurisdiction: US
Classification: Method of Use
Expires: 2031-02-26
Drug substance claim: No
Drug product claim: No
Assignee: Ambit Bioscience Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.